Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 9

Initial assessment of the benefits of implementing pharmacogenetics into the medical management of patients in a long-term care facility

Authors Saldivar J, Taylor D, Sugarman E, Cullors A, Garces J, Oades K, Centeno J

Received 31 July 2015

Accepted for publication 24 November 2015

Published 19 January 2016 Volume 2016:9 Pages 1—6


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Martin Bluth

Video abstract presented by Juan-Sebastian Saldivar

Views: 824

Juan-Sebastian Saldivar, David Taylor, Elaine A Sugarman, Ali Cullors, Jorge A Garces, Kahuku Oades, Joel Centeno

AltheaDx, San Diego, CA, USA

Abstract: The health care costs associated with prescription drugs are enormous, particularly in patients with polypharmacy (taking more than five prescription medications), and they continue to grow annually. The evolution of pharmacogenetics has provided clinicians with a valuable tool that allows for a smarter, more fine-tuned approach to treating patients for a number of clinical conditions. Applying a pharmacogenetics approach to the medical management of patients can provide a significant improvement to their care, result in cost savings by reducing the use of ineffective drugs, and decrease overall health care utilization. AltheaDx has begun a study to look at the benefits associated with incorporating pharmacogenetics into the medical management of patients who are on five or more medications. Applying pharmacogenetic guided PharmD recommendations across this patient population resulted in the elimination and/or replacement of one to three drugs, for 50% of the polypharmacy patient population tested, and an estimated US$621 in annual savings per patient. The initial assessment of this study shows that there is a clear opportunity for concrete health care savings solely from prescription drug management when incorporating pharmacogenetic testing.

Keywords: personalized medicine, pharmacogenetics, pharmacokinetics, pharmacodynamics, adverse drug reaction, polypharmacy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]